To CBD or not to CBD?: What pharmacists need to know

Biopharmaceuticals: what pharmacists need to know

A T THE beginning of the 20th century the medicines market was dominated by preparations derived from natural sources of plant, animal or mineral origin. Later these were replaced by synthetic molecules discovered in the laboratory and produced in large scale chemical plants. These drugs had an advantage over the natural products because they were consistent in their molecular structure and cou...

Molecular approaches to diagnosis of invasive aspergillosis what we know and what we do not know.

Invasive aspergillosis (IA) are a major complication in immunocompromized patients where can be serious and rapidly fatal. Early diagnosis and early appropriate antifungal treatment is important in reducing mortality and morbidity. But despite many efforts to develop detection methods, the diagnosis of IA still remains challenging and current conventional methods are limited for adequate diagno...

Ebola virus disease: what canadian hospital pharmacists need to know.

The ongoing epidemic of Ebola virus disease (EVD) in West Africa has been the most catastrophic in history, with widespread transmission in Guinea, Liberia, and Sierra Leone.1 As of March 2015, there had been over 25 000 probable, suspected, or confirmed cases and more than 10 000 deaths.1Cases have also appeared in other countries, including the United States.1 In response to the epidemic, the...

Do We Know What We Do not Know? A Response to Celine Bonnet

Coronavirus disease 2019 (COVID-19): What we need to know (In Press)